Contineum MS drug stumbles in mid-stage trial

Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints

Neurocrine review highlights key differences between tardive dyskinesia drugs

Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension

The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks

Alkem launches globally acclaimed De Simone Probiotic in India, expands GI portfolio

The formulation is backed by over 80 clinical trials and 200 scientific publications

Siolta Therapeutics’ novel microbiome therapy shows promise in preventing allergic diseases in infants

FDA nod to Koselugo for adults with Rare NF1 tumors, expanding life-changing treatment

Lilly expands biotech footprint with new Gateway Labs in Philadelphia

The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies

Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases

Time Medical launches India’s first low-field TOF MRI for nationwide aneurysm screening

India presents one of the world’s largest untapped opportunities for neurovascular screening